News | November 11, 2024
Zydus Wellness Q2 FY25 sales up 12% at Rs. 490.7 Cr
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
